MX2022007961A - Nuevos anticuerpos anti-fgfr2b. - Google Patents
Nuevos anticuerpos anti-fgfr2b.Info
- Publication number
- MX2022007961A MX2022007961A MX2022007961A MX2022007961A MX2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A
- Authority
- MX
- Mexico
- Prior art keywords
- novel anti
- fgfr2b
- antibodies
- fgfr2b antibodies
- same
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente divulgación proporciona anticuerpos anti-FGFR2b o fragmentos de unión a antígenos de estos, polinucleótidos aislados que codifican los mismos, composiciones farmacéuticas que los comprenden y los usos de estos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019127904 | 2019-12-24 | ||
PCT/CN2020/138659 WO2021129672A1 (en) | 2019-12-24 | 2020-12-23 | Novel anti-fgfr2b antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007961A true MX2022007961A (es) | 2022-07-12 |
Family
ID=76575671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007961A MX2022007961A (es) | 2019-12-24 | 2020-12-23 | Nuevos anticuerpos anti-fgfr2b. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230052680A1 (es) |
EP (1) | EP4081547A4 (es) |
JP (1) | JP2023508174A (es) |
KR (1) | KR20220119144A (es) |
CN (1) | CN114846029A (es) |
AR (1) | AR120886A1 (es) |
AU (1) | AU2020412088A1 (es) |
CA (1) | CA3160812A1 (es) |
MX (1) | MX2022007961A (es) |
TW (1) | TW202136311A (es) |
WO (1) | WO2021129672A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023185778A1 (en) * | 2022-03-28 | 2023-10-05 | Genor Biopharma Co., Ltd. | Novel anti-fgfr2 antibodies |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
MX2011000455A (es) * | 2008-11-07 | 2011-02-25 | Galaxy Biotech Llc | Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos. |
CN105263962B (zh) * | 2013-03-19 | 2019-12-31 | 北京盛诺基医药科技股份有限公司 | 抗体及用于治疗与雌激素受体相关疾病的方法 |
NZ715201A (en) * | 2013-08-01 | 2021-12-24 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
BR112018010410A8 (pt) * | 2015-11-23 | 2019-02-26 | Five Prime Therapeutics Inc | método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1 |
BR112019023898A2 (pt) * | 2017-05-16 | 2020-06-09 | Five Prime Therapeutics Inc | método para tratamento de câncer gástrico, uso de um anticorpo e composição |
-
2020
- 2020-12-23 KR KR1020227025532A patent/KR20220119144A/ko unknown
- 2020-12-23 JP JP2022539176A patent/JP2023508174A/ja active Pending
- 2020-12-23 MX MX2022007961A patent/MX2022007961A/es unknown
- 2020-12-23 US US17/788,733 patent/US20230052680A1/en active Pending
- 2020-12-23 CA CA3160812A patent/CA3160812A1/en active Pending
- 2020-12-23 EP EP20904516.0A patent/EP4081547A4/en active Pending
- 2020-12-23 CN CN202080090068.7A patent/CN114846029A/zh active Pending
- 2020-12-23 AU AU2020412088A patent/AU2020412088A1/en active Pending
- 2020-12-23 AR ARP200103630A patent/AR120886A1/es unknown
- 2020-12-23 WO PCT/CN2020/138659 patent/WO2021129672A1/en unknown
- 2020-12-24 TW TW109145975A patent/TW202136311A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA3160812A1 (en) | 2021-07-01 |
US20230052680A1 (en) | 2023-02-16 |
WO2021129672A1 (en) | 2021-07-01 |
EP4081547A4 (en) | 2024-02-21 |
EP4081547A1 (en) | 2022-11-02 |
KR20220119144A (ko) | 2022-08-26 |
JP2023508174A (ja) | 2023-03-01 |
TW202136311A (zh) | 2021-10-01 |
AU2020412088A1 (en) | 2022-06-23 |
AR120886A1 (es) | 2022-03-30 |
CN114846029A (zh) | 2022-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002111A (es) | Novedosos anticuerpos anti-cldn18.2. | |
MX2020003093A (es) | Anticuerpos anti-cd19 novedosos. | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
WO2019224718A3 (en) | Psma binding agents and uses thereof | |
WO2020039321A8 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
WO2018109170A3 (en) | Il-11ra antibodies | |
WO2017106684A3 (en) | Antibodies specifically binding hla-dr and their uses | |
MX2020003087A (es) | Anticuerpos anti-cd3epsilon novedosos. | |
WO2017214458A3 (en) | Anti-cd98 antibodies and antibody drug conjugates | |
WO2017214462A3 (en) | Anti-cd98 antibodies and antibody drug conjugates | |
MX2023008423A (es) | Anticuerpos anti-gremlin1 novedosos. | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
MX2022014896A (es) | Anticuerpos anti-cldn18.2 y usos para diagnostico de los mismos. | |
EP3957723A3 (en) | Engineered ligase variants | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
MX2021013417A (es) | Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos. | |
EP4273165A3 (en) | Interferon beta antibodies and uses thereof | |
IL285651A (en) | Anti-trem2 antibodies, preparations containing them and their uses | |
ZA202106602B (en) | Claudin 6 antibodies and uses thereof | |
WO2018069871A3 (en) | Anti-kras binding proteins | |
AU2019321490A8 (en) | Ox40-binding polypeptides and uses thereof | |
EP3856242A4 (en) | ANTI-SIGLEC ANTIBODIES, PHARMACEUTICAL COMPOSITION COMPRISING IT, AND THEIR USES | |
WO2018138681A9 (en) | Hemagglutinin-specific antibodies and uses thereof | |
EP3947466A4 (en) | ANTI-HLA-DQ2.5 ANTIBODIES | |
WO2020123330A3 (en) | Anti-alpha-synuclein antibodies and uses thereof |